Overview of thymosin activity
- PMID: 215305
Item in Clipboard
Overview of thymosin activity
Cancer Treat Rep.
1978 Nov.
Abstract
Our current research program centers around the biologic and chemical characterization of the family of polypeptides present in thymosin fraction 5. A system of nomenclature has been developed and the peptides are being systematically isolated and chemically characterized. Thymosin fraction 5 and its component parts influence a variety of lymphocyte properties including cyclic nucleotide levels, migration inhibitory factor production, T-dependent antibody production, and expression of certain surface markers. Thymosin is being used in clinical trials to investigate its effects on immunodeficiency diseases, malignant diseases, and autoimmune diseases.
Similar articles
-
Experiences with thymosin in primary immunodeficiency disease.Cancer Treat Rep. 1978 Nov;62(11):1779-85. Cancer Treat Rep. 1978. PMID: 215306
-
Thymosin: basic properties and clinical application in the treatment of immunodeficiency diseases and cancer.Recent Results Cancer Res. 1980;75:100-5. doi: 10.1007/978-3-642-81491-4_16. Recent Results Cancer Res. 1980. PMID: 6262885
-
In vitro induction of Lyt surface markers on precursor cells incubated with thymosin polypeptides.Cancer Treat Rep. 1978 Nov;62(11):1739-47. Cancer Treat Rep. 1978. PMID: 310340
-
Thymosin: basic properties and clinical potential in the treatment of patients with immunodeficiency diseases and cancer.Antibiot Chemother (1971). 1978;24:47-59. doi: 10.1159/000401500. Antibiot Chemother (1971). 1978. PMID: 350140 Review. No abstract available.
-
Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation.Ann N Y Acad Sci. 1979;332:33-48. doi: 10.1111/j.1749-6632.1979.tb47095.x. Ann N Y Acad Sci. 1979. PMID: 394636 Review.
Cited by
-
Treatment of patients with small-cell lung cancer at the Memorial Sloan-Kettering Cancer Center, 1974-1979.World J Surg. 1981 Sep;5(5):689-94. doi: 10.1007/BF01657928. World J Surg. 1981. PMID: 6277090 No abstract available.
-
Immunomodulation and therapeutic characterization of thymosin fraction five.Cancer Immunol Immunother. 1984;18(3):185-94. doi: 10.1007/BF00205510. Cancer Immunol Immunother. 1984. PMID: 6239686 Free PMC article.